LCID
Lucid Group, Inc.
LCID has a slight edge over MNRO overall, supported by stronger fundamentals and stronger modeled upside.
MNRO
Monro, Inc.
MNRO has lower modeled downside risk, despite its lower overall score.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MNRO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
MNRO's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
MNRO PE Valuation
MNRO has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
MNRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect MNRO's earnings and profitability to decline, with its revenue holding steady.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID has the edge over MNRO on earnings, with more consistent year-over-year improvement.
MNRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.00 | +$0.69 |
| Q2 2026 | $0.23 | +$0.92 |
| Q1 2026 | $0.03 | +$0.25 |
| Q4 2025 | -$0.49 | -177% |
| Q3 2025 | -$0.69 | -179% |
| Q2 2025 | -$0.69 | -163% |
| Q1 2025 | -$0.22 | -119% |
| Q4 2024 | $0.64 | -41% |
MNRO is still losing money, but far less than before: $0.00 per share over the past year, against $0.69 at its worst in mid-2025.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over MNRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
MNRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $283.6M | -1.8% |
| Q2 2026 | $287.1M | -4.6% |
| Q1 2026 | $273.8M | -7.2% |
| Q4 2025 | $293.4M | -4% |
| Q3 2025 | $288.9M | -4.1% |
| Q2 2025 | $301M | +2.7% |
| Q1 2025 | $295M | -4.9% |
| Q4 2024 | $305.8M | -3.7% |
MNRO's revenue has slid since its 2022 peak: $284M last quarter, down 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.9% | -3.5 points |
| Q2 2026 | 1.3% | +3.3 points |
| Q1 2026 | -1.9% | +6.2 points |
| Q4 2025 | 6.3% | +3.1 points |
| Q3 2025 | 4.4% | 0 points |
| Q2 2025 | -2% | -6.5 points |
| Q1 2025 | -8.1% | -11 points |
| Q4 2024 | 3.3% | -3.5 points |
MNRO has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
MNRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.8M | +8.2% |
| Q2 2026 | -$37.9M | -$28.6M |
| Q1 2026 | $12.4M | -47% |
| Q4 2025 | $9.1M | +15% |
| Q3 2025 | $26.6M | -54% |
| Q2 2025 | -$9.3M | -156% |
| Q1 2025 | $23.2M | +$35.1M |
| Q4 2024 | $7.9M | -73% |
MNRO has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
MNRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +1.1M shares |
| 1 year | -0.2% | -68K shares |
| 3 years | -3% | -977K shares |
| 5 years | -8% | -2.7M shares |
| Available history | -7.9% | -2.7M shares |
MNRO has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q1 2023 | — |
| Q4 2022 | $25.7M |
| Q3 2022 | $54M |
| Q2 2022 | $17.2M |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MNRO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 1.7x | Healthy |
| Q1 2025 | 1.0x | Very low |
| Q4 2024 | 0.8x | Very low |
MNRO's net debt is about 1.5 years of its operating earnings (EBITDA), about the same as a year ago.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
MNRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 5.4 | Oversold |
MNRO's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
MNRO PE vs Consumer Cyclical Sector
| Metric | MNRO | Sector median | Relative |
|---|---|---|---|
| PE | 58x | 18x | 219% above |
| PE % | 85 | 47 | 38 pts above |
MNRO has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
MNRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 18% below |
| 20 week MA | $13.5 | 23% below |
| 50 week MA | $16.4 | 37% below |
| 100 week MA | $16.8 | 38% below |
| 200 week MA | $25.1 | 59% below |
MNRO is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
MNRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.9 | $53.1 | -33% |
| 2021 | $53.1 | $59.2 | +11% |
| 2022 | $59.2 | $45.2 | -24% |
| 2023 | $45.2 | $29.3 | -35% |
| 2024 | $29.3 | $24.8 | -16% |
| 2025 | $24.8 | $20.8 | -16% |
| 2026 YTD | $20.8 | $10.4 | -50% |
MNRO has the edge over LCID on returns for 2026, with the stronger performance.